US equities |
TSLA $357.85 ▼-1.27% MU $894.44 ▼-3.95% NVDA $216.91 ▼-0.15% AAPL $343.70 ▲+0.50% SPCX $145.76 ▼-1.92% META $719.82 ▼-2.29% SNDK $1,331.65 ▼-4.53% MSFT $528.69 ▼-1.99%
FinancialContent

89bio, Inc. - Common Stock (NQ:ETNB)

14.84 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 89bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? ↗
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
News headline image
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH ↗
Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
Via Investor's Business Daily
News headline image
The Week Ahead: What's Next ↗
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
News headline image
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- 
From 89bio, Inc.
Via GlobeNewswire
News headline image
ETNB Stock Earnings: 89bio Misses EPS for Q1 2024 ↗
ETNB stock results show that 89bio missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio to Participate in the BofA Securities 2024 Health Care Conference
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET 
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
News headline image
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
News headline image
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
89bio to Participate in the Leerink Partners Global Biopharma Conference
From 89bio, Inc.
Via GlobeNewswire
News headline image
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
News headline image
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment ↗
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
News headline image
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena ↗
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
News headline image
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development ↗
89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
Via Benzinga
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
News headline image
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From 89bio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >